Investor Relations

PAINWeek 2023

Watch Video

Ensysce Biosciences 2021 Annual Letter

View Letter

Recent Event

European Pharmaceutical Market Research Association (EPHMRA) Annual Conference

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Company Overview

Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the fear of and the potential for opioid misuse, abuse and overdose. Our current development pipeline includes two new drug platforms - an abuse-resistant prodrug technology – the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection prodrug technology - the Multi-Pill Abuse Resistant, or the MPAR™ platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR™ platform when combined with our TAAP prodrugs is designed not only to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat is an ingredient in our overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Stock Snapshot

IR Contacts


Ensysce Biosciences, Inc.
7946 Ivanhoe Ave
Suite 201
La Jolla, CA 92037
T: 858-263-4196

Investor Relations

MZ North America
5055 Avenida Encinas
Suite 130
Carlsbad, CA 92008
T: 203-741-8811

Shannon Devine

Transfer Agent

Continental Stock Transfer & Trust Company
1 State Street
30th Floor
New York, NY 10004-1561
T: 212-509-4000

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.